Dr David Vickers, from the University of Calgary in Canada, said the “research exaggerates the role of HSV-1, failing to appreciate its absence in 99.56% of Alzheimer’s disease cases”.
He added: “The observed 17% hazard reduction with anti-herpetic drugs translates to a mere nine-month delay in Alzheimer’s disease onset.”